To the editor:
Role of GATA-1s in early hematopoiesis and differences between alternative splicing in human and murine GATA-1
We read with interest the description by Hoeller et al of an exon 2 GATA-1 mutation leading to severe transient myeloproliferative disease (TMD), 1 in which the authors speculated that the severe phenotype might reflect loss of both full-length (FL) GATA-1 and the shorter isoform, GATA-1s, due to the position of the mutation in codon 2. Although almost all GATA-1 mutations in children with Down syndrome are in exon 2 [2] [3] [4] and lead to loss of GATA-1FL, exon 2 mutations are also predicted to leave GATA-1s protein production unaffected, 4 by translation of an alternatively spliced mRNA comprising exons 1/3/4/5/6. 2 In humans, alternative splicing producing an exon 1/2/3/4/5/6 mRNA for GATA-1FL and exon 1/3/4/5/6 splice variant for GATA-1s has been demonstrated in adult bone marrow CD34 ϩ cells. 2 Using exon 1 and 3 primers, we have also found that both variants are consistently expressed in all normal cord blood and second-trimester fetal liver and bone marrow cells we have tested (n ϭ 12; Figure 1A ). It seems likely, therefore, that exon 2 mutations would still allow expression of GATA-1s mRNA, which may be difficult to detect at the protein level due to the relative insensitivity of commercial GATA-1 antibodies in immunohistochemical reactions. Interestingly, and by contrast, although mice produce the 2 Gata-1 isoforms by alternative translation of a single mRNA, 5 Gata-1s transcripts have not been reported in murine tissues and, in our experience, exon 1 and 3 primers consistently amplify only the FL transcript in mice ( Figure  1B ) despite evidence of Gata-1s protein production ( Figure 1C ). Further investigation of the functional consequences of different GATA-1 mutations may shed further light on the enigmatic role of GATA-1s in early hematopoiesis and differences between alternative splicing in human and murine GATA-1. To the editor:
Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
After observing high response rates in relapsed multiple myeloma (MM) patients, 1 we examined a 3-drug combination of bortezomib, cyclophosphamide, and dexamethasone (CyBorD) in newly diagnosed symptomatic patients. This phase 2 trial was open at Mayo Clinic Arizona and Princess Margaret Hospital, Toronto, was approved by the institutional review board/research ethics board of both centers, and was monitored by the Mayo Clinic Cancer Center Data and Safety Monitoring Board. Eligibility requirements were age 18 years or older, Eastern Cooperative Oncology Group performance status less than or equal to 2, Creatinine less than 3.5 mg/dL, absolute neutrophil count 1000/L or more, platelets 100 000/L or more, and informed signed consent. Patients had to have measurable disease. The primary end point of the study was confirmed response after 4 cycles (16 weeks). Responses were assessed according to modified EBMT criteria. 2 The first 33 patients (cohort 1) received 300 mg/m 2 of cyclophosphamide by mouth on days 1, 8, 15, 22, 1.3 mg/m 2 of bortezomib intravenously on days 1, 4, 8 and 11, and 40 mg of dexamethasone by mouth on days 1 to 4, 9 to 12, and 17 to 20. As we reported, 3 the ORR (Ն PR) was 88%, with 61% VGPR or better. High-dose dexamethasone and bortezomib can both be associated with toxicities, treatment delays and discontinuation which may limit efficacy. To maximize dose delivery and reduce toxicity, we modified the original schedule and accrued 30 additional patients: cohort 2 received the same weekly cyclophosphamide schedule, 1.5 mg/m 2 of bortezomib intravenously on days 1, 8, 15, 22 , and dexamethasone as in cohort 1 for cycles 1 and 2, then 40 mg once weekly for cycles 3 and 4.
The trial required 30 patients in each cohort to test the null hypothesis that the true success proportion in this patient population is at most 20%.
Cohort 1 had more International Staging System stages II/III than cohort 2 (67% vs. 44%) but cohorts were otherwise comparable. The overall response (Ն PR) for all 63 patients is 90% with 41% CR/nCR and 60% VGPR or better (Table 1) . For those completing all 4 cycles of therapy (n ϭ 55), the ORR is 95% with 47% CR/nCR and 67% VGPR or better. Patients in the once weekly bortezomib cohort achieved responses similar to the twice weekly cohort (ORR 93% vs 88%, Ն VGPR 60% vs 61%) and experienced less grade 3/4 adverse events (37%/3% vs 48%/12%). Fewer dose reductions of bortezomib and dexamethasone were required in the modified schedule and neuropathy rates were the same in both cohorts even though the total bortezomib dose per cycle was higher in the weekly versus the twice weekly schedule (6.0 mg/m 2 vs 5.2/mg/m 2 ).
CyBorD is a highly efficacious regimen and arguably as active as any 2-or 3-drug regimen reported to date. [4] [5] [6] [7] We have had the ability to study 2 different dosing schedules of this combination and have shown both to be very active but one appears less toxic and is more convenient for the patient. A prospective, randomized, clinical trial to confirm these results seems warranted. The weekly bortezomib dosing with low-dose dexamethasone has become our preferred induction regimen for transplant eligible patients. Gr Ն 3 Thrombocytopenia 21% 0%
Gr Ն 3 Neutropenia 12% 7%
Gr Ն 3 Anemia 9% 0%
Gr Ն 3 PN 6% 0%
Any Gr PN 64% 57%
Bortezomib doses reduced 21% 13%
Dex dose reduced 30% 20%
ITT indicates intention to treat; ORR, overall response; CR, complete response; nCR, near complete response; VGPR, very good partial response; GR, grade; AE, adverse event; and PN, peripheral neuropathy.
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